Normal pregnancy in a woman with nesidioblastosis treated with somatostatin analog octreotide.
OBJECTIVE
We report the case of a 36-yr-old woman with nesidioblastosis treated throughout pregnancy with high doses of octreotide. We studied the course of blood glucose, foetal growth and development.


METHODS
Blood samples were obtained every month throughout pregnancy and taken at birth from the umbilical cord. Sonography was performed repeatedly to monitor foetal growth.


RESULTS
The daily dose of octreotide was adapted to blood glucose levels: a dose of 1000 microg was infused during the first part of pregnancy, then it was decreased step by step during the last trimester of gestation. An elective cesarean section was performed at 32 weeks of gestation. High octreotide concentrations were obtained during the first part of gestation (range 2888-5021 pg/ml). During the third trimester of pregnancy blood glucose increased despite high insulin levels attesting physiological insulin-resistance. Plasma levels of placental GH and IGF-1 levels were similar to those observed in a normal pregnancy. Despite the presence of octreotide in the umbilical cord, TSH, free T4, PRL and pituitary GH concentrations were normal at birth. The female newborn (weight 3520 g, length 52 cm) had no malformation, and presented with normal postnatal development.


CONCLUSIONS
Our study demonstrates that: 1) octreotide treatment can be effective in controlling endogenous hyperinsulinism during pregnancy; 2) octreotide does not affect physiological changes during pregnancy such as insulin-resistance or placental GH level; 3) exposure of the foetus to octreotide throughout pregnancy does not induce any malformation and does not affect foetal development.
Boulanger
C
C
Department of Endocrinology, Rangueil University Hospital Centre,Toulouse, France.
Vezzosi
D
D
Bennet
A
A
Lorenzini
F
F
Fauvel
J
J
Caron
P
P
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D005765:Gastrointestinal Agents / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007328:Insulin; D007334:Insulin-Like Growth Factor I; D046768:Nesidioblastosis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D015282:Octreotide / Q000097:blood / Q000627:therapeutic use*; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D013004:Somatostatin / Q000378:metabolism
D001786:Blood Glucose; D005765:Gastrointestinal Agents; D007328:Insulin; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide